Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a prominent player in the pharmaceutical industry with a market capitalization of $748 billion, will present the primary overall survival analysis from ...

Eli Lilly's CDK4/6 inhibitor Verzenio reduced the risk of death by 15.8% when used as adjuvant treatment for early-stage HR-positive, HER2-negative breast cancer, according the reveal of data from the ...

Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase III monarchE study, (NCT02763566), Verzenio plus ...

Last week will likely be remembered as the one in which pharma frustrations with the UK boiled over. MSD's decision to pull back from a £1 billion ($1.35 billion) investment in the country was bad ...

PS Portal’s gargantuan, game-changing update is beginning to roll out around the world, allowing you to stream over 2,800 ...

Credit: Environmental Microbiology (2025). DOI: 10.1111/1462-2920.70188 A Curtin University-led international study has solved the mystery of how the skin of a fossilized fish was able to be preserved ...

With less than two months to go until Emily in Paris returns to our screens (December 18, BTW), I recently started a little rewatch to prepare myself for season 5. And while the Team Gabriel vs. Team ...

Death daddy Pluto is going direct in the sign of the strange -- here are the zodiac signs that will feel the shift most acutely. NY Post photo composite Pluto, our planet of profound change and ...

In 2022, Regeneron paid Sanofi $900 million to gain full rights to its partnered cancer drug Libtayo. Three years later, the pricey bet on the injected PD-1 inhibitor appears to be paying off.